Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin lispro - Eli Lilly and Company

Drug Profile

Insulin lispro - Eli Lilly and Company

Alternative Names: Humalog; Humalog Junior KwikPen; Humalog N; Humalog U 200; insulin lispro injection - Eli Lilly and Company; LY 275585; LY-8888AX; Lys-B28, Pro-B29; Lyspro

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 05 Oct 2023 Clinical trials in Diabetes mellitus (Treatment-experienced) in France (SC) (NCT05893797)
  • 15 Jun 2023 Eli Lilly and Company plans clinical trial for Type 1 diabetes mellitus and Type 2 diabetes mellitus (Treatment-experienced) (NCT05893797)
  • 04 Oct 2021 Cipla in-licensed marketing rights from Eli Lilly and Company for insulin lispro in India
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top